211 related articles for article (PubMed ID: 17124721)
1. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
[TBL] [Abstract][Full Text] [Related]
2. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Schloot NC; Meierhoff G; Lengyel C; Vándorfi G; Takács J; Pánczél P; Barkai L; Madácsy L; Oroszlán T; Kovács P; Sütö G; Battelino T; Hosszufalusi N; Jermendy G
Diabetes Metab Res Rev; 2007 May; 23(4):276-85. PubMed ID: 17103487
[TBL] [Abstract][Full Text] [Related]
3. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
4. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients.
Huurman VA; Decochez K; Mathieu C; Cohen IR; Roep BO
Diabetes Metab Res Rev; 2007 May; 23(4):269-75. PubMed ID: 17024692
[TBL] [Abstract][Full Text] [Related]
5. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial.
Raz I; Elias D; Avron A; Tamir M; Metzger M; Cohen IR
Lancet; 2001 Nov; 358(9295):1749-53. PubMed ID: 11734230
[TBL] [Abstract][Full Text] [Related]
6. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes.
Huurman VA; van der Meide PE; Duinkerken G; Willemen S; Cohen IR; Elias D; Roep BO
Clin Exp Immunol; 2008 Jun; 152(3):488-97. PubMed ID: 18422727
[TBL] [Abstract][Full Text] [Related]
7. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes.
Elias D; Avron A; Tamir M; Raz I
Ann N Y Acad Sci; 2006 Oct; 1079():340-4. PubMed ID: 17130576
[TBL] [Abstract][Full Text] [Related]
8. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
Buzzetti R; Cernea S; Petrone A; Capizzi M; Spoletini M; Zampetti S; Guglielmi C; Venditti C; Pozzilli P;
Diabetes; 2011 Nov; 60(11):3067-72. PubMed ID: 21896927
[TBL] [Abstract][Full Text] [Related]
9. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
10. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D
Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988
[TBL] [Abstract][Full Text] [Related]
11. DiaPep277 (DeveloGen).
Giannoukakis N
Curr Opin Investig Drugs; 2005 Oct; 6(10):1043-50. PubMed ID: 16259226
[TBL] [Abstract][Full Text] [Related]
12. Effect of pioglitazone on the course of new-onset type 1 diabetes mellitus.
Tafuri KS; Godil MA; Lane AH; Wilson TA
J Clin Res Pediatr Endocrinol; 2013; 5(4):236-9. PubMed ID: 24379032
[TBL] [Abstract][Full Text] [Related]
13. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results.
Eldor R; Kassem S; Raz I
Diabetes Metab Res Rev; 2009 May; 25(4):316-20. PubMed ID: 19267355
[TBL] [Abstract][Full Text] [Related]
14. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial.
Raz I; Ziegler AG; Linn T; Schernthaner G; Bonnici F; Distiller LA; Giordano C; Giorgino F; de Vries L; Mauricio D; Procházka V; Wainstein J; Elias D; Avron A; Tamir M; Eren R; Peled D; Dagan S; Cohen IR; Pozzilli P;
Diabetes Care; 2014; 37(5):1392-400. PubMed ID: 24757230
[TBL] [Abstract][Full Text] [Related]
15. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.
Tuccinardi D; Fioriti E; Manfrini S; D'Amico E; Pozzilli P
Expert Opin Biol Ther; 2011 Sep; 11(9):1233-40. PubMed ID: 21751937
[TBL] [Abstract][Full Text] [Related]
16. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal.
Pozzilli P; Raz I; Peled D; Elias D; Avron A; Tamir M; Eren R; Dagan S; Cohen IR
Diabetes Care; 2014; 37(5):1384-91. PubMed ID: 24408401
[TBL] [Abstract][Full Text] [Related]
19. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus.
Gabbay MA; Sato MN; Finazzo C; Duarte AJ; Dib SA
Arch Pediatr Adolesc Med; 2012 Jul; 166(7):601-7. PubMed ID: 22751874
[TBL] [Abstract][Full Text] [Related]
20. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
